← All indications
Deficiency Diseases
A condition produced by dietary or metabolic deficiency. The term includes all diseases caused by an insufficient supply of essential nutrients, i.e., protein (or amino acids), vitamins, and minerals. It also includes an inadequacy of calories. (From Dorland, 27th ed; Stedman, 25th ed)
Subtype terms (5)
More specific conditions that are subtypes of Deficiency Diseases in the MeSH hierarchy.
- Avitaminosis
13 drugs (9 approved, 4 experimental)
- Magnesium Deficiency
16 drugs (13 approved, 3 experimental)
- Potassium Deficiency
- Protein Deficiency
3 drugs (2 approved, 1 experimental)
- Swayback
Drugs by status
Phase 4 trials (29)
- metformin
- allopurinol
- 23-valent pneumococcal polysaccharide vaccine
- oxytocin
- exenatide
- methylphenidate
- alpha-1 antitrypsin
- fibrinogen (human)
- hydrocortisone
- icosapent ethyl
- hydroxyapatite silica
- human factor ix complex (prothrombin complex concentrate)
- febuxostat
- immune globulin (human)
- typhoid vi polysaccharide vaccine
- estradiol
- imiglucerase
- thiamine
- lisdexamfetamine
- bupropion
- atomoxetine
- degarelix acetate
- prednisolone
- trimethoprim
- amphetamine
- selenium
- human immunoglobulin g
- 20-valent pneumococcal conjugate vaccine
- mitapivat
Phase 3 trials (28)
- corticotropin
- pegylated arginine deiminase
- porcine brain-derived peptide preparation
- copper histidine
- sodium dichloroacetate
- elamipretide
- ganaxolone
- plasminogen
- bovine colostrum
- vitamin c
- magnesium sulfate
- testosterone
- nicotinamide
- capecitabine
- zidovudine
- oxaliplatin
- pyridoxine
- fenfluramine
- riboflavin
- glucose monohydrate
- sintilimab
- zinc
- Paternal Facial Pheromone
- triticum aestivum pollen
- COVID-19 convalescent plasma
- pyridoxal phosphate anhydrous
- inz-701
- glm101
Phase 2 trials (47)
- thymidine
- vitamin d3
- alipogene tiparvovec
- vitamin e
- anti cd45 monoclonal antibody
- acetylcysteine
- bezafibrate
- busulfan
- carglumic acid
- cd3,cd19 depleted hematopoietic stem cells
- prednisone
- progesterone
- fludrocortisone
- fomepizole
- hemopoietic stem cell
- leptin
- sodium phenylbutyrate
- acyline
- dutasteride
- donepezil
- mannose binding lectin
- sapropterin
- sebelipase alfa
- celecoxib
- cyclosporine
- mycophenolate
- rotigotine
- cyclophosphamide
- stem cells
- sulfamethoxazole
- +17 more
Phase 1 trials (18)
- brimonidine
- ferric derisomaltose
- copper gluconate
- somatropin
- glycerol phenylbutyrate
- calcium
- ketone
- kisspeptin
- azd8848
- methylene blue
- coagulation factor viia (recombinant)
- primaquine
- triptorelin
- multivitamins
- coagulation factor xiii a-subunit (recombinant)
- sargramostim
- autologous adipose-derived mesenchymal stem cells
- zf874
Other trials (63)
- levofloxacin
- melatonin
- maltose
- heparin
- iron
- sucrose
- beta-hydroxybutyrate
- calcium lactate
- chenodeoxycholic acid
- chlorella
- cholic acid
- dark chocolate
- egg
- folic acid
- l-glutamine
- glycerin
- mecasermin
- soybean oil
- cobalamin
- amoxicillin
- tryptophan
- levocarnitine
- ursodeoxycholic acid
- niacin
- red blood cells
- red clover
- platelets
- phosphatidylcholine
- s-1
- semaglutide
- +33 more
Organizations
Organization Involved with Phase 4 Indications (22)
- Daiichi Sankyo
- Genzyme
- Grifols
- J. Uriach and Company
- JW Pharmaceutical
- Unipharm, Inc.
- Ain Shams University
- Clinica Fabia Mater
- Hospital de Granollers
- Osaka University
- University of Athens
- Assiut University
- General Hospital of Chalkida
- University of Ulsan
- American University of Beirut
- El Galaa Teaching Hospital
- AMAG Pharmaceuticals, Inc.
- State University of New York, Buffalo
- Washington University in St. Louis
- Gensavis Pharmaceuticals, LLC
- Christian Medical College, Vellore, India
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (32)
- Zeria Pharmaceutical
- Schwarz Pharma
- Roche
- Sandoz
- Parexel
- Pharmacosmos
- Shield Therapeutics
- Vifor Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Baylor University
- University of London
- Ifakara Health Institute
- Mansoura University
- University of Toronto
- Prince of Songkla University
- Zhejiang University
- University of Basel
- University of Vienna
- University of Indonesia
- Watson Pharmaceuticals
- Auerbach Hematology and Oncology
- Keryx
- Fraunhofer
- J. W. Goethe University
- ICON
- Tigermed Consulting Co., Ltd
- BioStata
- ClinStar, LLC
- LabCorp
- Therapure Biopharma
- +2 more
Organization Involved with Phase 2 Indications (23)
- Takeda
- Ovid Therapeutics Inc.
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Children's National Research Institute
- University of Pennsylvania
- University of Pittsburgh
- Case Western Reserve University
- Harvard University
- Emory University
- Johns Hopkins University
- Stanford University
- University of Michigan
- Wayne State University
- Columbia University
- University of California, Los Angeles
- Icahn School of Medicine at Mount Sinai
- Food and Drug Administration
- University of Paris
- Children's National Medical Center
- University of Colorado
- George Washington University
- European Leukodystrophy Association
- Chinese Academy of Medical Sciences
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (8)